Tesetaxel for HER2(-) Metastatic Breast Cancer
Español  |  中國傳統的  |  简体中文
Call us  (855) 528-7322
Main Menu

Tesetaxel for HER2(-) Metastatic Breast Cancer

Sponsor: Odonate Therapeutics, LLC

Protocol ODO-TE-B301: A randomized, phase 3 trial of tesetaxel plus a reduced dose of capecitabine versus capecitabine alone for patients with locally advanced or metastatic HER2 negative and hormone receptor positive breast cancer that has previously been treated with a taxane in the adjuvant or neoadjuvant setting.